This supports previous work demonstrating that in areas with high prevalence of EGFR mutation, the performance of the LENT score can be improved by re-scoring lung adenocarcinomas from the highest to the lowest risk category (EGFR-LENT) [24]. The gene discussed is EGFR; the disease is lung adenocarcinoma.